Literature DB >> 33575042

Psychometric Properties of Preference-Based Measures for Economic Evaluation in Amyotrophic Lateral Sclerosis: A Systematic Review.

Nicole Peters1, Vanina Dal Bello-Haas1, Tara Packham1, Ava Mehdipour1, Ayse Kuspinar1.   

Abstract

OBJECTIVE: The aim of this review was to synthesize the psychometric properties of generic preference-based measures (PBMs) of health-related quality of life (HRQL) in Amyotrophic Lateral Sclerosis (ALS).
METHODS: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Four databases were searched from inception to April 2019: OVID Medline, Embase, PsycINFO, and CINAHL. Studies were included if (1) the sample represented individuals with ALS, (2) a generic PBM was utilized and reported on, and (3) information on the psychometric property of a generic PBM was provided.
RESULTS: Ninety-one articles were screened, and 39 full-text articles were reviewed. Seven full-text articles were included in this review. The mean age of participants ranged from 58.1 to 63.8 years, and mean time since diagnosis ranged from 20.5 to 44.6 months. Two generic PBMs were found, the EQ-5D-3L (n = 6) and the Quality of Well-Being Self-Administered (QWB-SA) scale (n = 1). Convergent validity of the EQ-5D-3L was large against a global scale of self-perceived health (r = 0.60) and small to large against ALS specific HRQL measures (r = 0.19 to 0.75). For the QWB-SA scale, correlations were small against a generic measure (r = 0.21) and large against ALS specific measures (r = 0.55). The EQ-5D-3L discriminated across different disease severity; however, floor effects were reported.
CONCLUSION: This review highlights the need for more rigorously designed studies to assess the psychometric properties of generic PBMs in ALS and the development of an ALS specific PBM that adequately reflects the health concerns of individuals with ALS.
Copyright © 2021 Nicole Peters et al.

Entities:  

Year:  2021        PMID: 33575042      PMCID: PMC7861917          DOI: 10.1155/2021/6681554

Source DB:  PubMed          Journal:  Neurol Res Int        ISSN: 2090-1860


  34 in total

Review 1.  Amyotrophic lateral sclerosis.

Authors:  L P Rowland; N A Shneider
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group.

Authors:  C Bombardier; J Raboud
Journal:  Control Clin Trials       Date:  1991-08

3.  Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Yaroslav Winter; Karsten Schepelmann; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Björn Tackenberg; Veit Mylius; Jens-Peter Reese; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 4.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.

Authors:  Louise Longworth; Yaling Yang; Tracey Young; Brendan Mulhern; Mónica Hernández Alava; Clara Mukuria; Donna Rowen; Jonathan Tosh; Aki Tsuchiya; Pippa Evans; Anju Devianee Keetharuth; John Brazier
Journal:  Health Technol Assess       Date:  2014-02       Impact factor: 4.014

5.  Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis.

Authors:  C Green; G Kiebert; C Murphy; J D Mitchell; M O'Brien; A Burrell; P N Leigh
Journal:  Qual Life Res       Date:  2003-08       Impact factor: 4.147

6.  Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.

Authors:  Nick Bansback; Aki Tsuchiya; John Brazier; Aslam Anis
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

7.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

Review 8.  A comprehensive review of amyotrophic lateral sclerosis.

Authors:  Sara Zarei; Karen Carr; Luz Reiley; Kelvin Diaz; Orleiquis Guerra; Pablo Fernandez Altamirano; Wilfredo Pagani; Daud Lodin; Gloria Orozco; Angel Chinea
Journal:  Surg Neurol Int       Date:  2015-11-16

Review 9.  Epidemiology of amyotrophic lateral sclerosis: an update of recent literature.

Authors:  Elisa Longinetti; Fang Fang
Journal:  Curr Opin Neurol       Date:  2019-10       Impact factor: 5.710

10.  Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis.

Authors:  Ashley R Jones; Naheed Jivraj; Rubika Balendra; Caroline Murphy; Joanna Kelly; Marie Thornhill; Carolyn Young; Pamela J Shaw; P Nigel Leigh; Martin R Turner; I Nick Steen; Paul McCrone; Ammar Al-Chalabi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-02-07       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.